Back |
home / stock / roiv / roiv message board
Subject | By | Source | When |
---|---|---|---|
Added a lot on the dip... | MWM | investorshub | 10/04/2021 3:09:12 PM |
I want more... | MWM | investorshub | 10/04/2021 2:23:43 PM |
https://www.dermavant.com/dermavant-showcases-new-long-term-data-from-phase-3-ps | rstar | investorshub | 10/04/2021 2:20:11 PM |
Dermavant Closer to FDA Approval for Tapinarof | aries4747 | investorshub | 10/04/2021 12:59:50 PM |
7 Companies Using AI for Drug Discovery | aries4747 | investorshub | 10/04/2021 12:57:27 PM |
Very interesting. Full approval not far off? | MWM | investorshub | 10/04/2021 12:40:39 PM |
Dermavant Showcases New Long-Term Data from Phase 3 | aries4747 | investorshub | 10/04/2021 12:19:53 PM |
an effective cream for psoriasis would be groundbreaking- | rstar | investorshub | 10/04/2021 12:01:51 PM |
Nine current $ROIV Vants. Wonder which six | aries4747 | investorshub | 10/02/2021 5:26:12 PM |
Since that deal, two Sumitovant companies, Urovant and | aries4747 | investorshub | 10/02/2021 5:18:15 PM |
The only thing I learned from Fridays opening | aries4747 | investorshub | 10/02/2021 5:02:00 PM |
Enzyvant was part of this deal. | aries4747 | investorshub | 10/02/2021 4:44:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...